John W. LaRocca - 17 Jan 2025 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
22 Jan 2025, 18:57:56 UTC
Prior SEC filing
16 Jan 2025
Next SEC filing
18 Sep 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ John LaRocca
Filing notes and source

Key filing fact

John W. LaRocca filed Form 4 for Y-mAbs Therapeutics, Inc. (YMAB) on 22 Jan 2025.

Key facts

  • This page summarizes John W. LaRocca's Form 4 filing for Y-mAbs Therapeutics, Inc. (YMAB).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 22 Jan 2025, 18:57.

Change

  • Previous filing in this sequence was filed on 16 Jan 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

YMAB transaction

Common Stock

Award

Transaction value
$0
Shares
+21,500
Change %
Price
$0.000000
Shares after
21,500
Date
17 Jan 2025
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

YMAB transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
$0
Shares
+42,900
Change %
Price
$0.000000
Shares after
42,900
Date
17 Jan 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
42,900
Exercise price
$6.16
Footnotes
F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU. The RSUs vest by 1/3 on each of January 17, 2026, January 17, 2027 and January 17, 2028, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Footnote F2

Represents stock options granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan.

Footnote F3

The stock options shall vest and become exercisable as to 25% of the shares subject to the option on January 17, 2026, and thereafter vest and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .